
UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial
For mothers with prenatal depression, a single low dose of esketamine after childbirth decreases major depressive episodes at 42 days post partum by about three quarters.
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach
We hypothesize that at subanesthetic doses, ketamine produces a unique spectrum of altered states, ranging from psychoactive to deep ego-dissolving experiences, that are intrinsic to ketamine’s therapeutic effects.
Oral ketamine may offer a solution to the ketamine conundrum
Evidence suggests that low-dose oral ketamine is clinically effective in treating pain. This may also be due to the actions of norketamine and therefore, its relevance to the mental health context is explored in this narrative review.
Ketamine for depression - Knowns, unknowns, possibilities, barriers, and opportunities
Ketamine has the potential to change our approach to the clinical management of depression if knowledge, attitudinal, and regulatory barriers can be overcome, and if risks related to comorbidities and concurrent medications are addressed by close supervision.
Randomized trial of ketamine masked by surgical anesthesia in patients with depression
Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials
Esketamine nasal spray versus quetiapine for treatment-resistant depression
In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8.
The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression
Our integrative model aims to bridge the biomedical-psychedelic divide to offer a feasible, flexible, and standardized approach to ketamine for TRD. Our learnings from developing and implementing this psychedelic-inspired model for severe, real-world patients in two academic hospitals may offer valuable insights for the ongoing roll-out of a range of psychedelic therapies.
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Our findings suggested that effect sizes for depression severity, as well as response and remission rates, were numerically greater for racemic ketamine than esketamine.
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth
Ketamine was associated with comparable clinical benefits, safety, and tolerability in a TAY sample as compared to a matched GA TRD sample.
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Patients reported several esketamine effects with psychotherapeutic potential, such as increased openness, detachment, an interruption of negativity, and mystical-type experiences.
Ketamine versus ECT for nonpsychotic treatment-resistant major depression
Ketamine was noninferior to ECT as therapy for treatment-resistant major depression without psychosis.
One-year outcomes following intravenous ketamine plus digital training among patients with treatment-resistant depression: A secondary analysis of a randomized clinical trial
Our study found that the rapid effects of ketamine can be made more enduring with simple, portable, digital techniques.
Could ketamine-assisted therapy help treat alcohol disorder?
A new £2.4 million phase III trial delivered through seven NHS sites across the UK will investigate whether ketamine-assisted therapy could help treat alcohol disorder.